Propagenix is a preclinical-stage platform technology company that is applying its unique technology to both internal and partnered cell therapy programs. The company is engaged in the development and commercialization of technology which originated from the laboratory of Dr. Richard Schlegel of Georgetown University.
Of course, I am always interested in technologies transferred from Georgetown, because I attended the university for Graduate Studies in Biochemistry and Molecular Biology.
Headquartered in Rockville, Maryland, Progagenix was founded in 2014 by Brian Pollok, Ph.D. Pollok is the company’s Co-Founder, as well as its current President and CEO. I am honored to release this interview in which we discuss the company’s core technology, its preclinical-stage programs, and future goals. Enjoy.